NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis → Biden’s Tax Plan Could Destroy Your Retirement Savings! (From GoldenCrest Metals) (Ad) Free VYGR Stock Alerts $8.47 -0.33 (-3.75%) (As of 12:15 PM ET) Add Compare Share Share Today's Range$8.46▼$8.7750-Day Range$7.42▼$9.3352-Week Range$6.06▼$14.07Volume117,408 shsAverage Volume755,680 shsMarket Capitalization$460.68 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Voyager Therapeutics alerts: Email Address Voyager Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside104.5% Upside$18.00 Price TargetShort InterestBearish7.83% of Shares Sold ShortDividend StrengthN/ASustainability-0.97Upright™ Environmental ScoreNews Sentiment1.12Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.39) to ($1.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.21 out of 5 starsMedical Sector309th out of 917 stocksBiological Products, Except Diagnostic Industry45th out of 152 stocks 3.4 Analyst's Opinion Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Voyager Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.83% of the outstanding shares of Voyager Therapeutics have been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Voyager Therapeutics has recently decreased by 1.84%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVoyager Therapeutics has received a 71.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Voyager Therapeutics is -0.97. Previous Next 2.3 News and Social Media Coverage News SentimentVoyager Therapeutics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Voyager Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -84% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.53% of the stock of Voyager Therapeutics is held by insiders.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Voyager Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Voyager Therapeutics are expected to decrease in the coming year, from ($1.39) to ($1.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is -175.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is -175.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Voyager Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. Just take a look: Claim your free seat by clicking here now. About Voyager Therapeutics Stock (NASDAQ:VYGR)Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Read More VYGR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYGR Stock News HeadlinesJune 13 at 4:01 PM | globenewswire.comVoyager Therapeutics to Present at Multiple Virtual Investor ConferencesJune 13 at 9:15 AM | markets.businessinsider.comVoyager Therapeutics Appoints Nathan Jorgensen As New CFO June 13 at 7:00 AM | globenewswire.comVoyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial OfficerJune 5, 2024 | americanbankingnews.comCritical Contrast: Voyager Therapeutics (NASDAQ:VYGR) vs. SpringWorks Therapeutics (NASDAQ:SWTX)May 16, 2024 | finance.yahoo.comVoyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s DiseaseMay 16, 2024 | globenewswire.comVoyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's DiseaseMay 15, 2024 | benzinga.comLatest News for Voyager Therapeutics Stock (NASDAQ:VYGR)May 14, 2024 | finanznachrichten.deVoyager Therapeutics, Inc.: Voyager Therapeutics Reports First Quarter 2024 Financial and Operating ResultsMay 14, 2024 | markets.businessinsider.comPositive Outlook for Voyager Therapeutics: Buy Rating Affirmed Amid Pipeline Progress and Strong Financial PositionMay 14, 2024 | msn.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comQ1 2024 Voyager Therapeutics Inc Earnings CallMay 14, 2024 | finance.yahoo.comVoyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 13, 2024 | sfgate.comVoyager Therapeutics: Q1 Earnings SnapshotMay 13, 2024 | msn.comVoyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats by $10.02MMay 13, 2024 | globenewswire.comVoyager Therapeutics Reports First Quarter 2024 Financial and Operating ResultsMay 10, 2024 | msn.comVoyager 1 was in crisis in interstellar space. NASA wouldn’t give up.May 8, 2024 | msn.comThe Invincible - Official Voyager Update TrailerMay 8, 2024 | msn.com8 Coolest Starships in Star Trek: VoyagerMay 8, 2024 | finance.yahoo.comVoyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual MeetingMay 6, 2024 | finance.yahoo.comVoyager Therapeutics' (NASDAQ:VYGR) three-year earnings growth trails the splendid shareholder returnsMay 6, 2024 | globenewswire.comVoyager Therapeutics Announces First Quarter 2024 Conference Call and WebcastApril 30, 2024 | msn.comScientist Warns That NASA’s Voyager Probes Are “Dodging Bullets Out There”April 29, 2024 | msn.com7 Star Trek: Voyager Alien Villains Worse Than Discoverys BreenApril 27, 2024 | msn.comSilent no more: NASA hears from Voyager 1, the most distant spacecraftApril 26, 2024 | yahoo.comInside NASA's 5-month fight to save the Voyager 1 mission in interstellar spaceSee More Headlines Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/14/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VYGR CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees162Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$30.00 Low Stock Price Target$8.00 Potential Upside/Downside+104.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$132.33 million Net Margins-2.56% Pretax Margin-1.95% Return on Equity-1.28% Return on Assets-0.85% Debt Debt-to-Equity RatioN/A Current Ratio5.64 Quick Ratio5.64 Sales & Book Value Annual Sales$250.01 million Price / Sales1.91 Cash Flow$3.08 per share Price / Cash Flow2.86 Book Value$5.37 per share Price / Book1.64Miscellaneous Outstanding Shares54,390,000Free Float51,930,000Market Cap$478.63 million OptionableOptionable Beta1.04 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Alfred W. Sandrock Jr. (Age 66)M.D., Ph.D., President, CEO & Director Comp: $1.01MMs. Robin Swartz (Age 53)COO, Principal Financial & Accounting Officer and Acting Chief Business Officer Comp: $661.98kMs. Jacquelyn Fahey Sandell Esq. (Age 53)J.D., Chief Legal Officer Comp: $538.16kDr. Krystof Bankiewicz M.D.Ph.D., FounderDr. Guangping Gao Ph.D.Founder & Member of Scientific Advisory BoardDr. Mark A. Kay M.D. (Age 65)Ph.D., Founder Dr. Phillip D. Zamore Ph.D.Founder & Member of Scientific Advisory BoardMr. Todd Carter Ph.D. (Age 54)Chief Scientific Officer Ms. Michelle Quinn SmithChief Human Resources OfficerDr. Maria Lopez-Bresnahan M.B.A.M.D., Senior Vice President of Translational Medicine & Clinical DevelopmentMore ExecutivesKey CompetitorsAdverum BiotechnologiesNASDAQ:ADVMbluebird bioNASDAQ:BLUEJounce TherapeuticsNASDAQ:JNCECASI PharmaceuticalsNASDAQ:CASIApplied Genetic TechnologiesNASDAQ:AGTCView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCBought 1,000,000 shares on 5/24/2024Ownership: 4.214%Ikarian Capital LLCSold 125,000 shares on 5/17/2024Ownership: 0.333%Plato Investment Management LtdBought 4,119 shares on 5/17/2024Ownership: 0.008%Virtus Investment Advisers Inc.Bought 12,648 shares on 5/16/2024Ownership: 0.023%California State Teachers Retirement SystemSold 1,271 shares on 5/16/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions VYGR Stock Analysis - Frequently Asked Questions Should I buy or sell Voyager Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VYGR shares. View VYGR analyst ratings or view top-rated stocks. What is Voyager Therapeutics' stock price target for 2024? 7 brokerages have issued 1 year price objectives for Voyager Therapeutics' stock. Their VYGR share price targets range from $8.00 to $30.00. On average, they predict the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 104.5% from the stock's current price. View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts. How have VYGR shares performed in 2024? Voyager Therapeutics' stock was trading at $8.44 at the start of the year. Since then, VYGR shares have increased by 4.3% and is now trading at $8.80. View the best growth stocks for 2024 here. When is Voyager Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our VYGR earnings forecast. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.24. The business earned $19.52 million during the quarter, compared to analyst estimates of $10.33 million. Voyager Therapeutics had a negative trailing twelve-month return on equity of 1.28% and a negative net margin of 2.56%. What ETFs hold Voyager Therapeutics' stock? ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include Franklin Genomic Advancements ETF (HELX).iShares Neuroscience and Healthcare ETF (IBRN). What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT). Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.94%), Farallon Capital Management LLC (4.21%), Price T Rowe Associates Inc. MD (1.92%), Acadian Asset Management LLC (0.85%), Ikarian Capital LLC (0.33%) and ClariVest Asset Management LLC (0.18%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VYGR) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.